Skip to Main content Skip to Navigation
Journal articles

EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.

Abstract : EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.
Document type :
Journal articles
Complete list of metadatas

Cited literature [31 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-01573832
Contributor : Anaïs Victoire <>
Submitted on : Thursday, August 10, 2017 - 4:28:04 PM
Last modification on : Thursday, September 3, 2020 - 4:30:04 PM

File

2870-46383-3-PB.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Farah Khayati, Laura Pérez-Cano, Kamel Maouche, Aurélie Sadoux, Zineb Boutalbi, et al.. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.. Oncotarget, Impact journals, 2015, 6 (12), pp.9766-80. ⟨10.18632/oncotarget.2870⟩. ⟨pasteur-01573832⟩

Share

Metrics

Record views

547

Files downloads

844